All women with multiple sclerosis should start hormone replacement therapy at menopause unless contraindicated: No

Bove R Okai A Houtchens M , et al. Effects of menopause in women with multiple sclerosis: An evidence-based review. Front Neurol 2021; 12: 554375.

Magyari M Koch-Henriksen N . Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2022; 93(7): 716–722.

Graves JS Henry RG Cree BAC , et al. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology 2018; 90(3): e254–e260.

Bove R White C Fitzgerald K , et al. Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis. Neurology 2016; 87(14): 1457–1463, http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L612541285%5Cnhttp://dx.doi.org/10.1212/WNL.0000000000003176%5Cnhttp://rug.on.worldcat.org/atoztitles/link/?sid=EMBASE&issn=1526632X&id=doi:10.1212%2FWNL.0000000000003176&atitle=Horm

Gold S Voskuhl R . Estrogen and testosterone therapies in MS. Brain 2009; 6123(09): 239–251.

Kopp TI Lidegaard Ø Magyari M . Hormone therapy and disease activity in Danish women with multiple sclerosis: A population-based cohort study. Eur J Neurol 2022; 29(6): 1753–1762.

Bove R Healy BC Musallam A , et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler 2016; 22(7): 935–943.

Pinkerton JV . Hormone therapy for postmenopausal women. N Engl J Med 2020; 382(5): 446–455.

Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V Gaitskell K , et al. Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385(9980): 1835–1842.

Pourhadi N Mørch LS Holm EA , et al. Menopausal hormone therapy and dementia: Nationwide, nested case-control study. BMJ 2023; 381: e072770.